title: Peri- and postinterventional antithrombotic therapy in TAVI. Do we need antiplatelet therapy?
abstract: Interventional treatment of aortic valve stenosis by transcatheter aortic valve replacement (TAVR) has become routine practice in elderly and high risk patients in recent years. Similar to other vascular interventional or surgical procedures TAVR carries thrombotic risks such as stroke, myocardial infarction or systemic embolism as well as peri-procedural bleeding risks. These risks comprise the access site, the type of prosthesis, and the individual risk profile of the patient. Not only during the peri-procedural period but also during longterm follow-up the current target population for TAVR procedures carries a high risk for thrombotic events in particular if atrial fibrillation is present. On the other hand side the bleeding risk is also increased in these patients. Thus, to provide the optimal strategy of antithrombotic therapy during and after TAVR remains a clinical challenge.
authors.affiliation: Martin Moser, Heart Center, University of Freiburg, Department of Cardiology and Angiology I, Südring 15, 79189 Bad Krozingen, Germany, Tel. + 49/(0)76 33/402 32 10, E-mail: martin.moser@universitaets-herzzentrum.de.
authors.forename: M
authors.initials: M
authors.lastname: Moser
mesh_terms: D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D011292:Premedication / Q000379:methods*; D013927:Thrombosis / Q000209:etiology* / Q000517:prevention & control*; D065467:Transcatheter Aortic Valve Replacement / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents
keywords: Transcatheter aortic valve replacement